Neuroproteases, called secretases, produce β–amyloid peptides, the abnormal accumulation of which is thought to cause Alzheimer's disease. Reducing β-amyloid peptide production by inhibiting these secretases is generally considered to be a likely means to successfully treat Alzheimer's disease.
Using proprietary secretase targets, we are developing small molecule inhibitors and have been successful in reducing brain β-amyloid peptide production in an Alzheimer’s disease animal model.
